
# Read & Publish Open Access initiative



# Development



The leading primary research journal in the field of developmental biology launched in 1953, Development publishes cutting-edge articles and reviews across the spectrum of plant and animal development.

Topic coverage ranges from stem cells and nuclear reprogramming to evolutionary developmental and systems biology, from neurobiology to regional specification, morphogenesis and organogenesis, and from epigenetics to the aetiology of disease.

In addition to primary research articles, Development publishes a range of commissioned review-based articles. These synthesise the latest advances in the field, put forward new hypotheses to provoke debate and inspire new research directions, and inform newcomers to the field.

Development was designated as one of the 100 most influential journals of the past 100 years by the SLA BioMedical & Life Sciences Division in 2019.

### Readership

Development is read by scientists at all levels and from a broad field of expertise – including plant and animal biologists, geneticists, molecular biologists, cell biologists, paediatricians, neurologists, embryologists and stem cell scientists.

### Abstracting and indexing services

Development is abstracted and/or indexed (amongst others) by: BIOBASE, CAB abstracts, Cambridge Scientific Abstracts, Current Contents, EMBASE, ISI Web of Science, Medline and SCOPUS.

### **Open Access commitment**

The Company of Biologists has a long-standing commitment to Open Access, and our subscription journals (including Development) were the first in the world to be awarded Transformative Journal status by Plan S. All our journals (including our fully Open Access journals – Disease Models & Mechanisms and Biology Open) are also included in our Read & Publish Open Access agreements.

### **Key metrics**

- 2021 Impact Factor: 6.862
- Five-year Impact Factor: 7.799
- Two-year citation median: 4.0
- Eigenfactor Score: 0.05234
- Article Influence Score: 2.738
- Immediacy index: 1.008
- h-index: 336
- Scopus CiteScore: 9.7
- SJR indicator: 2.886
- SNIP: 1.622

### Development

## Available through The Company of Biologists' Read & Publish Open Access initiative



### **Expert team of academic editors**

### **Editor-in-Chief**

• James Briscoe (Francis Crick Institute, UK)

#### **Deputy Editor**

• Steve Wilson (University College London, UK)

#### **Editors**

- Swathi Arur (MD Anderson Cancer Center, USA)
- Benoit Bruneau (Gladstone Institutes, USA)
- · Cassandra Extavour (Harvard University, USA)
- François Guillemot (Francis Crick Institute, UK)
- · Yka Helariutta (University of Cambridge, UK)
- Haruhiko Koseki (RIKEN Centre for Allergy and Immunology, Japan)
- · Thomas Lecuit (Marseille University, France)
- Liz Robertson (University of Oxford, UK)
- Debra Silver (Duke University, USA)
- · Patrick Tam (University of Sydney, Australia)
- Maria Elena Torres-Padilla (Helmholtz Centre, Munich, Germany)
- James Wells (Cincinatti Children's Hospital Medical Center, USA)

### **Associate Editors**

- Paul François (McGill University, Canada)
- Matthias Lutolf (École Polytechnique Fédérale de Lausanne, Switzerland)
- Irene Miguel-Aliaga (Imperial College London and MRC-LMS, UK)
- · Hanna Mikkola (University of California, Los Angeles, USA)
- Samantha Morris (Washington University in St Louis, USA)
- · Ken Poss (Duke University, USA)

### What are the benefits of Read & Publish agreements?

- Unlimited "read" access to our three subscription journals Development, Journal of Cell Science and Journal of Experimental Biology
- Uncapped fee-free Open Access publishing of research articles in our subscription journals plus our two fully Open Access journals – Disease Models & Mechanisms and Biology Open
- · Transparent cost-neutral pricing
- Single annual fee covers reading and publishing
- Easy to switch from a subscription to a Read & Publish agreement
- Compliant with funder mandates including Plan S
- What a wonderful surprise it was to find out about the Read & Publish Open Access agreement between The Company of Biologists and my university which facilitates immediate access to our research to all readers without charge!

This is fabulous: for science, for our trainees whose careers benefit from having their research seen quickly and widely, and for our hard-earned publicly funded research grants that can advance science further as a result.

I love this initiative.

Professor Jacquetta Trasler, McGill University, Canada

